CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Some non-regulatory announcements are only available in English. All announcements required under applicable law, regulation or code are available in English and Swedish.

2025

11 Mar 2025, 14:35
Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients
4 Mar 2025, 08:00
Hansa Biopharma to attend Leerink Partners Global Healthcare Conference
24 Feb 2025, 08:00
Hansa Biopharma to attend TD Cowen Healthcare Conference
6 Feb 2025, 07:00 | Regulatory
Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results
IDEFIRIX Product Sales Increased 83% Compared to the Prior Year
23 Jan 2025, 07:00
Hansa Biopharma to host Year-end report 2024 conference call
7 Jan 2025, 16:45
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

2024

17 Dec 2024, 21:40 | Regulatory
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
5 Dec 2024, 15:30
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
Data from the trial is expected to be shared in 2025
Load more

E-mail

Sign up to receive updates on the latest company news and filings

Choose type

I consent to Hansa Biopharma handling my personal data. See our Privacy Policy for information about how we handle personal data.

Thank you. You will get an e-mail message to activate your subscription.